{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T01:12:18Z","timestamp":1779325938416,"version":"3.51.4"},"reference-count":64,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gda\u0144sk Medical University","award":["221-02-0039\/07"],"award-info":[{"award-number":["221-02-0039\/07"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background and Objectives: Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression. Although many studies have been published, there is still not enough data on the effect of ketamine in combination with other medications. Particularly interesting is the combination of ketamine and lamotrigine, and its potential role in bipolar depression. The aim of this review was to identify animal and human studies in which ketamine and lamotrigine were used together in order to find out if there is scientific ground for combining ketamine and lamotrigine in the treatment of mood disorders. Directions for future studies are presented. Materials and Methods: PubMed and Web of Science were searched. Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA 2020 methodology was applied. Results: Seventeen studies were included for review. Animal studies using models of depression suggested a synergistic effect of ketamine and lamotrigine in combination. Studies on healthy humans showed a reduction in ketamine-induced dissociative symptoms with lamotrigine pretreatment. In a study on patients with depression, ketamine and lamotrigine did not have a stronger antidepressant effect than ketamine alone, but in this study only one ketamine infusion was administered. One case series described the antidepressant and anti-suicidal effect of the combination in two bipolar patients. Available clinical studies on patients with mood disorders did not support the hypothesis that lamotrigine reduces ketamine-induced dissociative symptoms. Conclusions: The results of the analyzed studies were not sufficient to answer any of the stated questions; however, they allowed us to delineate future research directions. The identified animal studies suggested a possible synergistic antidepressant effect of ketamine and lamotrigine. The available clinical studies were not conclusive. No controlled studies on large groups of bipolar patients with multiple ketamine infusions combined with lamotrigine treatment have been published so far. There is some evidence for the reduction of ketamine\u2019s side effects by lamotrigine, and there are reports suggesting that lamotrigine can reduce ketamine craving. More studies with follow-up are needed in order to investigate the ketamine\u2013lamotrigine combination in bipolar patients.<\/jats:p>","DOI":"10.3390\/cells11040645","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:32:30Z","timestamp":1644784350000},"page":"645","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review"],"prefix":"10.3390","volume":"11","author":[{"given":"Alina","family":"Wilkowska","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz S.","family":"Wiglusz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Jakuszkowiak-Wojten","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6343-8454","authenticated-orcid":false,"given":"Wies\u0142aw J.","family":"Cuba\u0142a","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jcph.1983","article-title":"ACCP Public Policy Committee Off-Label Use of Ketamine: A Challenging Drug Treatment Delivery Model with an Inherently Unfavorable Risk-Benefit Profile","volume":"62","author":"Pai","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: Seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of Ketamine\u2019s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid Resolution of Suicidal Ideation after a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients with Treatment-Resistant Major Depressive Disorder","volume":"71","author":"Diazgranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bdi.12487","article-title":"Ketamine vs. midazolam in bipolar depression with suicidal thoughts","volume":"19","author":"Grunebaum","year":"2017","journal-title":"Bipolar Disord."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","article-title":"A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression","volume":"275","author":"Zheng","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114892","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of Ketamine and its Metabolites as Antidepressants","volume":"197","author":"Hess","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","article-title":"Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications","volume":"73","author":"Highland","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1773","DOI":"10.1002\/mpr.1773","article-title":"The prevalence and diagnostic classification of mixed features in patients with major depressive episodes: A multicenter study based on the DSM-5","volume":"28","author":"Shim","year":"2019","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"ref_14","first-page":"566","article-title":"Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.05.010","article-title":"The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?","volume":"190","author":"Abdallah","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of \u03b1-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1523\/JNEUROSCI.20-01-00008.2000","article-title":"Positive Modulation of AMPA Receptors Increases Neurotrophin Expression by Hippocampal and Cortical Neurons","volume":"20","author":"Lauterborn","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0028-3908(00)00194-5","article-title":"Antidepressant-like actions of an AMPA receptor potentiator (LY392098)","volume":"40","author":"Li","year":"2001","journal-title":"Neuropharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2018.10.016","article-title":"The pharmacological management of Lennox-Gastaut syndrome and critical literature review","volume":"63","author":"Verrotti","year":"2018","journal-title":"Seizure"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.bjp.0705737","article-title":"Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat","volume":"142","author":"Ahmad","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(98)00580-9","article-title":"Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats","volume":"358","author":"Southam","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1017\/S1461145713000096","article-title":"The neurobiology of bipolar disorder: Identifying targets for specific agents and synergies for combination treatment","volume":"17","author":"Andreazza","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.npp.1301178","article-title":"The Anticonvulsants Lamotrigine, Riluzole, and Valproate Differentially Regulate AMPA Receptor Membrane Localization: Relationship to Clinical Effects in Mood Disorders","volume":"32","author":"Du","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1874467210902020207","article-title":"Mood-Stabilizers Target the Brain Arachidonic Acid Cascade","volume":"2","author":"Rao","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/089771503322584628","article-title":"Apoptosis of spinal cord neurons by preventing depletion nicotine attenuates arachidonic acid-induced of neurotrophic factors","volume":"20","author":"Garrido","year":"2003","journal-title":"J. Neurotrauma"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Caracciolo, L., Barbon, A., Palumbo, S., Mora, C., Toscano, C.D., Bosetti, F., and Barlati, S. (2011). Altered mRNA Editing and Expression of Ionotropic Glutamate Receptors after Kainic Acid Exposure in Cyclooxygenase-2 Deficient Mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019398"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1017\/S1461145711001003","article-title":"Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: Implications for its efficacy in bipolar disorder","volume":"15","author":"Ramadan","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11064-008-9817-3","article-title":"Chronic Administration of Mood Stabilizers Upregulates BDNF and Bcl-2 Expression Levels in Rat Frontal Cortex","volume":"34","author":"Chang","year":"2009","journal-title":"Neurochem. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1177\/0269881109359102","article-title":"The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: Role of brain-derived neurotrophic factor","volume":"24","author":"Li","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462009005000003","article-title":"Suicidal ideation and suicide attempts in bipolar disorder type I: An update for the clinician","volume":"31","author":"Abreu","year":"2009","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_32","first-page":"47","article-title":"Suicide and bipolar disorder","volume":"61","author":"Jamison","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1192\/bjp.2019.36","article-title":"Treatment-resistant and Multi-therapy resistant criteria for bipolar depression: Consensus definition\u2014CORRIGENDUM","volume":"214","author":"Berk","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1192\/bjp.bp.110.086983","article-title":"Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: Cohort study","volume":"200","author":"Li","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40345-019-0160-1","article-title":"Bipolar depression: A major unsolved challenge","volume":"8","author":"Baldessarini","year":"2020","journal-title":"Int. J. Bipolar Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"ref_38","first-page":"180","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","article-title":"Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review","volume":"24","author":"Veraart","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.biopha.2016.05.035","article-title":"Pharmacological evidence for the involvement of the NMDA receptor and nitric oxide pathway in the antidepressant-like effect of lamotrigine in the mouse forced swimming test","volume":"82","author":"Ostadhadi","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.pharep.2017.04.021","article-title":"Mechanism of synergistic action on behavior, oxidative stress and inflammation following co-treatment with ketamine and different antidepressant classes","volume":"69","author":"Matias","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00213-003-1421-2","article-title":"Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice","volume":"169","author":"Brody","year":"2003","journal-title":"Psychopharmacology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0269881107077718","article-title":"(+\/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics","volume":"21","author":"Cilia","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.biopsych.2006.01.020","article-title":"Ketamine Dose-Dependently Induces High-Frequency Oscillations in the Nucleus Accumbens in Freely Moving Rats","volume":"60","author":"Hunt","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2018.10.028","article-title":"Lamotrigine attenuates the motivation to self-administer ketamine and prevents cue- and prime-induced reinstatement of ketamine-seeking behavior in rats","volume":"194","author":"Lee","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the Neuropsychiatric Effects of Ketamine with Lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","article-title":"Glutamate and the Neural Basis of the Subjective Effects of Ketamine: A pharmaco-magnetic resonance imaging study","volume":"65","author":"Deakin","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/jpet.112.201665","article-title":"Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents","volume":"345","author":"Doyle","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1007\/s00213-015-4021-z","article-title":"Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects","volume":"232","author":"Shcherbinin","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1007\/s00213-015-3951-9","article-title":"Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile","volume":"232","author":"Joules","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"110074","DOI":"10.1016\/j.jclinane.2020.110074","article-title":"Lamotrigine for reducing ketamine-induced psychologic disturbances: A pilot randomized and blinded trial","volume":"68","author":"Maheshwari","year":"2020","journal-title":"J. Clin. Anesth."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/PRA.0000000000000316","article-title":"Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior","volume":"24","author":"Chan","year":"2018","journal-title":"J. Psychiatr. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mehy.2015.11.011","article-title":"Potential benefit of lamotrigine in managing ketamine use disorder","volume":"87","author":"Huang","year":"2016","journal-title":"Med Hypotheses"},{"key":"ref_55","first-page":"916360","article-title":"Failure of Ketamine Anesthesia in a Patient with Lamotrigine Overdose","volume":"2014","author":"Kornhall","year":"2014","journal-title":"Case Rep. Crit. Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.pnpbp.2008.04.009","article-title":"Modulation of high-frequency oscillations associated with NMDA receptor hypofunction in the rodent nucleus accumbens by lamotrigine","volume":"32","author":"Hunt","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Pavlovic, Z. (2011). Lamotrigine reduces craving and depressive symptoms in cocaine dependence. J. Neuropsychiatry Clin. Neurosci., 23.","DOI":"10.1176\/appi.neuropsych.23.1.E32"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-5618.2006.00292.x","article-title":"Effects of lamotrigine in patients with bipolar disorder and alcohol dependence","volume":"8","author":"Rubio","year":"2006","journal-title":"Bipolar Disord."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mao, Z., Bo, Q., Li, W., Wang, Z., Ma, X., and Wang, C. (2019). Prepulse inhibition in patients with bipolar disorder: A systematic review and meta-analysis. BMC Psychiatry, 19.","DOI":"10.1186\/s12888-019-2271-8"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41380-020-00964-4","article-title":"PKB\u03b2\/AKT2 deficiency impacts brain mTOR signaling, prefrontal cortical physiology, hippocampal plasticity and select murine behaviors","volume":"26","author":"Palumbo","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biopsych.2007.06.005","article-title":"AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families","volume":"63","author":"Thiselton","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_62","unstructured":"(2021, December 20). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020241s045s051lbl.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dean, R.L., Marquardt, T., Hurducas, C., Spyridi, S., Barnes, A., Smith, R., Cowen, P.J., McShane, R., Hawton, K., and Malhi, G.S. (2021). Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD011611.pub3"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:28Z","timestamp":1760134708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11040645"],"URL":"https:\/\/doi.org\/10.3390\/cells11040645","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]}}}